glp 1 and ckd Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products–induced inflammation Study uncovers how chronic kidney

By activating both GIP and GLP-1 receptors, Zepbound enhances insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and reduces appetite through central nervous system pathways

GLP-1 access without governance is not a strategy: 6 steps to better outcomes If youre a benefits leader right now, you may be living in two dashboards at once

Moderate kidney disease may allow semaglutide use with close monitoring, but severe renal impairment warrants avoidance

The STEP and SUSTAIN trial data provide robust evidence of systemic anti-inflammatory effects

Terushkin explains

This is great, well laid out and informative